Published in Clin Exp Pharmacol Physiol on February 25, 2005
Hemodynamic and hematologic profile of healthy adults ingesting dietary supplements containing 1,3-dimethylamylamine and caffeine. Nutr Metab Insights (2011) 1.19
A finished dietary supplement stimulates lipolysis and metabolic rate in young men and women. Nutr Metab Insights (2011) 1.13
Thermogenic effect of an acute ingestion of a weight loss supplement. J Int Soc Sports Nutr (2009) 1.07
Thermogenic effect from nutritionally enriched coffee consumption. J Int Soc Sports Nutr (2006) 1.01
Commonly Used Dietary Supplements on Coagulation Function during Surgery. Medicines (Basel) (2015) 0.97
Acute effects of ingesting Java Fittrade mark energy extreme functional coffee on resting energy expenditure and hemodynamic responses in male and female coffee drinkers. J Int Soc Sports Nutr (2007) 0.90
The acute effects of the thermogenic supplement Meltdown on energy expenditure, fat oxidation, and hemodynamic responses in young, healthy males. J Int Soc Sports Nutr (2008) 0.84
Cardiotoxicity of Ma Huang/caffeine or ephedrine/caffeine in a rodent model system. Toxicol Pathol (2007) 0.84
Thermogenic effect of meltdown RTD energy drink in young healthy women: a double blind, cross-over design study. Lipids Health Dis (2009) 0.83
A Review of Natural Stimulant and Non-stimulant Thermogenic Agents. Phytother Res (2016) 0.78
The effects of a fat loss supplement on resting metabolic rate and hemodynamic variables in resistance trained males: a randomized, double-blind, placebo-controlled, cross-over trial. J Int Soc Sports Nutr (2016) 0.76
The effects of a single-dose thermogenic supplement on resting metabolic rate and hemodynamic variables in healthy females - a randomized, double-blind, placebo-controlled, cross-over trial. J Int Soc Sports Nutr (2016) 0.76
Perspectives on Exertional Rhabdomyolysis. Sports Med (2017) 0.75
Cardiomyopathy Related to a Weight Loss Supplement: A Case Report and Review of Literature. J Investig Med High Impact Case Rep (2017) 0.75
Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control (2013) 7.69
Metabolism and disposition kinetics of nicotine. Pharmacol Rev (2005) 6.66
Cigarette smoking and infection. Arch Intern Med (2004) 5.04
Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation (2010) 4.50
Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol (2009) 4.16
Thirdhand tobacco smoke: emerging evidence and arguments for a multidisciplinary research agenda. Environ Health Perspect (2011) 3.69
Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) (2006) 3.68
Randomized Trial of Reduced-Nicotine Standards for Cigarettes. N Engl J Med (2015) 3.63
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther (2004) 3.49
Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther (2002) 3.36
Population approaches to improve diet, physical activity, and smoking habits: a scientific statement from the American Heart Association. Circulation (2012) 2.95
Formation of carcinogens indoors by surface-mediated reactions of nicotine with nitrous acid, leading to potential thirdhand smoke hazards. Proc Natl Acad Sci U S A (2010) 2.93
Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther (2006) 2.71
Maternal smoking during pregnancy and severe antisocial behavior in offspring: a review. Am J Public Health (2002) 2.64
Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol Biomarkers Prev (2007) 2.43
Nicotine reduction revisited: science and future directions. Tob Control (2010) 2.41
Nicotine intake and dose response when smoking reduced-nicotine content cigarettes. Clin Pharmacol Ther (2006) 2.35
Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 2.25
CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther (2006) 2.21
Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst (2008) 2.17
Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet (2008) 2.12
Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes. Cancer Epidemiol Biomarkers Prev (2012) 2.06
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med (2003) 2.02
Acute aortic dissection related to crack cocaine. Circulation (2002) 1.97
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Hemodynamic effects of ephedra-free weight-loss supplements in humans. Am J Med (2005) 1.94
Biomarkers increase detection of active smoking and secondhand smoke exposure in critically ill patients. Crit Care Med (2011) 1.86
Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst (2002) 1.83
Translational research in medication development for nicotine dependence. Nat Rev Drug Discov (2007) 1.81
Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Psychopharmacol (2006) 1.80
Nicotine, carbon monoxide, and carcinogen exposure after a single use of a water pipe. Cancer Epidemiol Biomarkers Prev (2011) 1.78
Mentholated cigarette smoking inhibits nicotine metabolism. J Pharmacol Exp Ther (2004) 1.77
Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res (2003) 1.76
Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res (2006) 1.75
Cytisine for smoking cessation: a research agenda. Drug Alcohol Depend (2007) 1.70
Determination of phenolic metabolites of polycyclic aromatic hydrocarbons in human urine as their pentafluorobenzyl ether derivatives using liquid chromatography-tandem mass spectrometry. Anal Chem (2007) 1.69
Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophr Res (2005) 1.64
Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clin Pharmacol Ther (2002) 1.63
Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure. Nicotine Tob Res (2011) 1.61
Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiol Biomarkers Prev (2011) 1.57
Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol Sci (2011) 1.55
A randomized trial of nicotine nasal spray in adolescent smokers. Pediatrics (2008) 1.55
Elimination kinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Cancer Epidemiol Biomarkers Prev (2009) 1.53
Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J Anal Toxicol (2006) 1.53
Cardiogenic shock after use of fluoroamphetamine confirmed with serum and urine levels. Clin Toxicol (Phila) (2014) 1.52
Prevalence of smoking assessed biochemically in an urban public hospital: a rationale for routine cotinine screening. Am J Epidemiol (2009) 1.52
Comparison of urine cotinine and the tobacco-specific nitrosamine metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and their ratio to discriminate active from passive smoking. Nicotine Tob Res (2011) 1.50
Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. Circulation (2010) 1.50
GHB urine concentrations after single-dose administration in humans. J Anal Toxicol (2006) 1.45
Reducing tobacco harm: research challenges and issues. Nicotine Tob Res (2002) 1.44
CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch Gen Psychiatry (2007) 1.44
Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics (2005) 1.43
Cytisine, the world's oldest smoking cessation aid. BMJ (2013) 1.41
Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev (2002) 1.41
Human pharmacology of the methamphetamine stereoisomers. Clin Pharmacol Ther (2006) 1.41
Urine nicotine metabolites and smoking behavior in a multiracial/multiethnic national sample of young adults. Am J Epidemiol (2007) 1.39
Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res (2006) 1.37
Comparison of nicotine and carcinogen exposure with water pipe and cigarette smoking. Cancer Epidemiol Biomarkers Prev (2013) 1.37
Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure. Nicotine Tob Res (2009) 1.36
Counseling to reduce children's secondhand smoke exposure and help parents quit smoking: a controlled trial. Nicotine Tob Res (2009) 1.36
Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev (2012) 1.34
Carcinogen exposure during short-term switching from regular to "light" cigarettes. Cancer Epidemiol Biomarkers Prev (2005) 1.31
Cotinine levels in relation to smoking behavior and addiction in young adolescent smokers. Nicotine Tob Res (2007) 1.30
Attitudes and practices of hookah smokers in the San Francisco Bay Area. J Psychoactive Drugs (2011) 1.29
Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics (2009) 1.28
Nicotine reduction: strategic research plan. Nicotine Tob Res (2012) 1.27
Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application. J Pharmacokinet Pharmacodyn (2007) 1.27
Higher nicotine and carbon monoxide levels in menthol cigarette smokers with and without schizophrenia. Nicotine Tob Res (2007) 1.26
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med (2009) 1.24
Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics (2013) 1.24
Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behav Pharmacol (2008) 1.22
Interlaboratory comparability of serum cotinine measurements at smoker and nonsmoker concentration levels: a round-robin study. Nicotine Tob Res (2009) 1.21
Longer term exposure to secondhand smoke and health outcomes in COPD: impact of urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Nicotine Tob Res (2009) 1.20
Intraindividual variability of plasma antioxidants, markers of oxidative stress, C-reactive protein, cotinine, and other biomarkers. Epidemiology (2006) 1.19
Exposure and kinetics of polycyclic aromatic hydrocarbons (PAHs) in cigarette smokers. Chem Res Toxicol (2012) 1.17
Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. J Natl Cancer Inst (2012) 1.17
Mutagen sensitivity has high heritability: evidence from a twin study. Cancer Res (2006) 1.16
Withdrawal in adolescent light smokers following 24-hour abstinence. Nicotine Tob Res (2009) 1.15
Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology (2011) 1.15
Thirdhand smoke causes DNA damage in human cells. Mutagenesis (2013) 1.14
Chinese 'low-tar' cigarettes do not deliver lower levels of nicotine and carcinogens. Tob Control (2010) 1.14
Human pharmacology of a performance-enhancing dietary supplement under resting and exercise conditions. Br J Clin Pharmacol (2008) 1.14
Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharmacol Ther (2003) 1.13
Chinese "herbal" cigarettes are as carcinogenic and addictive as regular cigarettes. Cancer Epidemiol Biomarkers Prev (2009) 1.13
The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiol Biomarkers Prev (2013) 1.13